- Home
- Editorial
- News
- Practice Guidelines
- Anesthesiology Guidelines
- Cancer Guidelines
- Cardiac Sciences Guidelines
- Critical Care Guidelines
- Dentistry Guidelines
- Dermatology Guidelines
- Diabetes and Endo Guidelines
- Diagnostics Guidelines
- ENT Guidelines
- Featured Practice Guidelines
- Gastroenterology Guidelines
- Geriatrics Guidelines
- Medicine Guidelines
- Nephrology Guidelines
- Neurosciences Guidelines
- Obs and Gynae Guidelines
- Ophthalmology Guidelines
- Orthopaedics Guidelines
- Paediatrics Guidelines
- Psychiatry Guidelines
- Pulmonology Guidelines
- Radiology Guidelines
- Surgery Guidelines
- Urology Guidelines
Oral immunotherapy in peanut allergy linked to anaphylaxis: Lancet
Oral immunotherapy in Peanut allergy is associated with increased risk for anaphylaxis, according to a meta-analysis. Despite inducing desensitization, peanut allergy oral immunotherapy increases a patient’s risk of allergic reactions compared with avoidance or placebo.
Allergic reactions involving the gastrointestinal tract, skin and mucous membranes, nose, and lungs also increased. The new study has appeared in the Lancet.
Oral immunotherapy is an emerging experimental treatment for peanut allergy, but its benefits and harms are unclear. The researchers in a systematic review analysed the efficacy and safety of oral immunotherapy versus allergen avoidance or placebo (no oral immunotherapy) for peanut allergy.
The researchers examined 12 trials in which over 1000 patients with peanut allergy were randomized to receive either oral immunotherapy or no oral immunotherapy (e.g., peanut avoidance, placebo).
It was found that during a median follow-up of 1 year, patients on oral immunotherapy were at higher risk for peanut-induced anaphylaxis compared to controls (relative risk, 3.1). The authors estimate that 151 more episodes of anaphylaxis per 1000 patients occurred because of oral immunotherapy. Other serious adverse events and epinephrine use were also more common in the treatment group. Oral immunotherapy was not associated with significantly better quality of life.
The authors concluded that in patients with peanut allergy, high-certainty evidence shows that available peanut oral immunotherapy regimens considerably increase allergic and anaphylactic reactions over avoidance or placebo, despite effectively inducing desensitisation. Safer peanut allergy treatment approaches and rigorous randomised controlled trials that evaluate patient-important outcomes are needed.
It was found that immunotherapy-related side-effects at home for allergic reactions to accidental exposures may decrease in some patients when they are out of the house namely in social situations. But it is not clear that which patients would benefit most and what the relative balance of reactions in and out of patients' homes would be.
Next Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd